Get startedLog in
    Picture of Biosenic SA logo

    BIOS — Biosenic SA News Story

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Bone Therapeutics Says It Submitted Clinical Trial Application For Pivotal JTA-004 Phase III study

    Picture of Biosenic SA logoBiosenic SA
    20/12/2019 06:03
    Dec 20 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * REG-BONE THERAPEUTICS ADVANCES JTA-004 INTO PIVOTAL PHASE
III
STUDY
    * CLINICAL TRIAL APPLICATION FOR PIVOTAL JTA-004 PHASE III
STUDY
SUBMITTED
    * START PATIENT ENROLLMENT ANTICIPATED EARLY 2020 WITH
TOPLINE
RESULTS EXPECTED IN Q2 2021

Source text for Eikon:  ID:nGNE1tjKvW 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))

    Recent news on Biosenic SA

    See all news